Mesoblast reports positive results from back pain trial

04/24/2013 | Australian Life Scientist

Preliminary results from a midstage trial indicate patients treated with Mesoblast's mesenchymal precursor cells experienced greater pain relief and increased function than those treated with hyaluronic acid alone. Patients who received 6 million cells responded better than those in a higher-dose group. The full results could open the door to a late-stage clinical trial.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL